Immunotherapy for bladder cancer spans two very different treatment approaches, and the side effects depend on which one you receive. Intravesical BCG (a live bacterial treatment instilled directly into the bladder) primarily causes local urinary symptoms, while systemic checkpoint inhibitors such as pembrolizumab, nivolumab, and atezolizumab can trigger immune reactions in virtually any organ. Both categories of side effects are manageable for most patients, but the range, timing, and severity differ enough that understanding what to watch for matters.
BCG and Local Bladder Side Effects
BCG (Bacillus Calmette-Guérin) remains the standard intravesical immunotherapy for non-muscle-invasive bladder cancer. It works by provoking a strong local immune reaction inside the bladder, and that same inflammation is what causes the side effects. In a large phase 3 trial of over 1,300 patients who started BCG, roughly 63% reported local side effects, about 31% had systemic side effects, and around 8% stopped treatment because of them. The single most common complaint was chemical cystitis, affecting about 35% of patients, while general malaise was the most frequent systemic symptom at around 16%.1PubMed. Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG
In practical terms, BCG cystitis means pain during urination, urgency, frequent bathroom trips, and sometimes incontinence. The underlying reason is that BCG triggers a vigorous inflammatory response in the bladder wall but does not simultaneously ramp up the tissue-repair pathways needed to heal the lining. This allows the bladder’s protective layer to break down, letting irritants from urine seep into the underlying tissue and keep the inflammation going.2PubMed Central. Treating BCG-Induced Cystitis with Combined Chondroitin and Hyaluronic Acid Instillations in Bladder Cancer These symptoms typically peak after each instillation and fade within a couple of days, though for some people the irritation becomes chronic enough to require treatment breaks or dose adjustments.
Less commonly, BCG can cause systemic reactions that go beyond general malaise: fever, joint pain, and rarely, a disseminated BCG infection. The fever is usually low-grade and self-limiting, but persistent high fevers or signs of BCG spreading outside the bladder require prompt medical evaluation and sometimes anti-tuberculosis drugs. The important thing to know is that BCG side effects are overwhelmingly local and urinary, and the systemic events that worry oncologists most are uncommon.
Checkpoint Inhibitor Side Effects Are a Different Animal
If BCG side effects are mostly about the bladder, checkpoint inhibitor side effects are about the whole body. Drugs like pembrolizumab, nivolumab, and atezolizumab work by releasing the brakes on your immune system so it can attack cancer cells more aggressively. The trade-off is that the immune system can also turn on healthy tissues, producing what clinicians call immune-related adverse events. These can show up in the skin, gut, lungs, liver, thyroid, pituitary gland, kidneys, nervous system, and heart, among other places.3PubMed Central. Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy
The sheer breadth is what makes checkpoint inhibitor toxicity tricky. Most patients will experience something mild, often fatigue or a skin rash. But the same drug can cause life-threatening inflammation of the heart or lungs in another patient, with little warning beforehand. Understanding the organ-specific patterns helps you and your medical team catch problems early.
Skin Reactions
Skin problems are among the most visible and common checkpoint inhibitor side effects. Rashes, itching, and dry skin are reported frequently. Most of these are mild and manageable with topical creams or antihistamines. More serious dermatologic reactions do occur, though. In one reported case, a patient with metastatic bladder cancer who started pembrolizumab experienced an acute flare of bullous pemphigoid, a blistering skin condition that had previously been inactive.4PubMed Central. Acute Flare of Bullous Pemphigus With Pembrolizumab Used for Treatment of Metastatic Urothelial Cancer This highlights a broader concern: checkpoint inhibitors can reactivate dormant autoimmune conditions or trigger entirely new ones. If you have a history of autoimmune disease, your oncologist will weigh that risk carefully before prescribing these drugs.
Gastrointestinal Problems
Diarrhea and colitis (inflammation of the colon) are well-known checkpoint inhibitor side effects. In clinical trial data for nivolumab in bladder cancer, severe diarrhea and colitis each occurred in just under 1% of patients, though milder diarrhea is more common.5Toxicology Reports. An overview of immune checkpoint inhibitor toxicities in bladder cancer That low percentage can be misleading, because when immune-mediated colitis does hit, it can be severe and stubborn.
A case report illustrates how difficult this can become: a 50-year-old woman with bladder cancer developed diarrhea two weeks after her first dose of checkpoint inhibitor therapy. Despite high-dose intravenous steroids, her symptoms recurred. She needed multiple rounds of infliximab (a powerful immune-suppressing drug), and a second scope showed worsening ulceration and bleeding in the colon.6American Journal of Gastroenterology. A Unique Case of Immunotherapy-Induced Colitis in a 50-year-old Female With Bladder Cancer This is not the typical experience, but it underscores why even seemingly mild diarrhea during checkpoint inhibitor therapy warrants a call to your treatment team. Catching colitis early, before it progresses to deep ulceration, leads to much better outcomes.
Endocrine Disruption
Your endocrine system, the collection of hormone-producing glands including the thyroid and pituitary, is a frequent target of immune-related side effects. The pattern depends on which checkpoint inhibitor you receive. Drugs that block CTLA-4 more commonly cause inflammation of the pituitary gland (hypophysitis), while PD-1 and PD-L1 inhibitors more often cause thyroid problems, including both overactive and underactive thyroid states.7PubMed Central. The side effects of immune checkpoint inhibitor therapy on the endocrine system
Endocrine side effects are particularly sneaky because their symptoms, such as fatigue, weight changes, feeling cold, or brain fog, overlap heavily with what cancer patients already experience from the disease itself or from general treatment fatigue. A case involving a 68-year-old man with bladder cancer shows how this can play out: after two cycles of immunotherapy combined with chemotherapy, he developed fever, loss of appetite, drowsiness, and eventually delirium. Lab work revealed very low cortisol and adrenal hormone levels, pointing to pituitary inflammation caused by the immunotherapy drug.8PubMed Central. Hypophysitis Induced by Sintilimab in the Treatment of Bladder Cancer: A Case Report Unlike some other immune-related side effects, endocrine damage from checkpoint inhibitors is often permanent. Many patients end up on lifelong hormone replacement for the affected gland, even after the immunotherapy itself is stopped.
Lung Inflammation
Pneumonitis, or inflammation of the lung tissue, is one of the side effects oncologists worry about most. It typically shows up roughly 6 to 12 weeks after starting treatment, though it can appear within days of the first infusion or many months later.9PubMed Central. Immune Checkpoint Inhibitor-associated Pneumonitis: A Narrative Review Symptoms like a new cough, shortness of breath, or chest discomfort should prompt immediate evaluation. The challenge is that these symptoms look a lot like a respiratory infection, and distinguishing between the two based on symptoms alone is difficult. Doctors often need imaging and sometimes a bronchoscopy to sort it out. In the nivolumab bladder cancer trial data, severe pneumonitis occurred in just under 1% of patients, similar to the rate for severe colitis.5Toxicology Reports. An overview of immune checkpoint inhibitor toxicities in bladder cancer
One complicating factor is that immune-related lung inflammation can appear alongside other immune side effects. A patient developing skin lesions and colitis at the same time as breathing difficulties should raise a flag for pneumonitis rather than infection, since checkpoint inhibitors can attack multiple organs simultaneously.9PubMed Central. Immune Checkpoint Inhibitor-associated Pneumonitis: A Narrative Review
When Side Effects Show Up, and How Long They Last
The timing of immune-related adverse events catches many patients off guard. Side effects can range from mild to life-threatening, and their onset is often delayed by several weeks or months after starting treatment.10PubMed Central. A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors Skin reactions tend to appear first, often within the first few weeks. Gastrointestinal and liver side effects typically arrive in the weeks to months range. Endocrine problems can emerge even later and, as noted earlier, frequently become permanent.
What is less commonly discussed is that side effects can appear long after you have finished treatment. In one study tracking patients over time, the cumulative probability of developing an immune-related adverse event was about 43% at 6 months, 51% at 12 months, and 57% at 24 months from the start of therapy.11PubMed. Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy That steady climb past the end of active treatment means you need ongoing monitoring even after your last infusion. Late-onset events are not just theoretical; they are common enough that follow-up bloodwork and symptom check-ins should continue for months after the treatment course wraps up.
Managing Side Effects When They Happen
The first-line treatment for most moderate-to-severe immune-related adverse events is corticosteroids (typically prednisone or methylprednisolone). For many patients, steroids bring symptoms under control. But a meaningful fraction of patients do not respond adequately to steroids alone. In one large review of over 1,300 cases, about 16% needed a second-line therapy beyond steroids. The most frequently used escalation drugs were TNF-alpha antagonists like infliximab (used in about 47% of second-line cases), intravenous immunoglobulins (about 19%), and mycophenolate mofetil (about 16%). Among patients who received these second-line treatments, roughly 74% had their symptoms resolve and another 13% improved, though about 4% ended up with permanent effects and another 4% died with symptoms ongoing.12PubMed. Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors
The choice of which second-line drug to use depends on which organ is affected. A systematic review recommended infliximab as first-line for steroid-resistant colitis (with vedolizumab as a backup), mycophenolate mofetil for steroid-resistant hepatitis and pneumonitis, and abatacept or anti-thymocyte globulin for steroid-resistant myocarditis, an especially dangerous condition. The review stressed that these additional drugs should be started promptly if steroids have not worked within about three days.13PubMed Central. Corticosteroid-resistant immune-related adverse events: a systematic review Speed matters because immune-related inflammation can escalate quickly, and waiting too long to switch strategies increases the risk of organ damage.
Combination Therapy Complicates the Picture
Bladder cancer treatment is increasingly moving toward combination regimens, and this creates new side-effect challenges. The combination of enfortumab vedotin (an antibody-drug conjugate) and pembrolizumab (a checkpoint inhibitor) has shown strong efficacy in advanced urothelial cancer, but the overlap in their side-effect profiles makes it hard to figure out which drug is causing which problem. Both drugs individually can cause skin reactions, pneumonitis, and diarrhea, so when a patient on the combination develops one of these, the clinical team faces a genuine puzzle.14PubMed Central. Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancer
Each drug also has its own signature side effects that help with attribution. Enfortumab vedotin is characterized by peripheral neuropathy (numbness and tingling in hands and feet), hyperglycemia (high blood sugar), taste changes, and eye problems. Pembrolizumab, on the other hand, has a lower overall burden of severe side effects but is the likelier culprit for immune-mediated endocrine problems, hepatitis, colitis, and nephritis. When both are given together, the diagnostic and management challenges multiply.15PubMed. Toxicity Attribution During Enfortumab Vedotin Plus Pembrolizumab Therapy in Urothelial Carcinoma: A Practical Framework Oncology teams use practical frameworks to try to sort out which drug to hold, which to dose-reduce, and which to discontinue, but this remains one of the harder judgment calls in bladder cancer care right now.
Restarting Immunotherapy After a Severe Reaction
If your treatment is stopped because of a serious immune-related event, the question of whether to try again is one of the most fraught decisions in oncology. Patients who tolerated their initial immunotherapy well are generally considered reasonable candidates for rechallenge, while those who had grade 3 or higher events (severe reactions requiring hospitalization or intensive treatment) need careful assessment before restarting.16PubMed Central. Current Status in Rechallenge of Immunotherapy
The evidence on rechallenge is still evolving, but the data so far is informative. In one review of 80 patients who were rechallenged with PD-1 inhibitors after prior severe immune-related events, half experienced some new adverse event. About a third had mild-to-moderate events, while roughly 18% had severe events again. Around 30% had to discontinue treatment, and 18% experienced a recurrence of the same type of side effect they originally had.17Journal for ImmunoTherapy of Cancer. Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy Those numbers mean rechallenge is not unreasonable, but it is far from risk-free. The decision typically involves weighing how well the cancer responded to immunotherapy, what other treatment options exist, and how severe and how reversible the original side effect was.
How Side Effects Affect Daily Life
Clinical trial reports focus on grading side effects by medical severity, but what patients actually care about is how the treatment makes them feel day to day. A study of 78 bladder cancer patients receiving chemotherapy or immunotherapy found that the symptoms most strongly linked to reduced quality of life were not necessarily the ones clinicians focused on most. Fatigue had one of the strongest connections to lost ability to carry out daily roles, while anxiety, sadness, and feeling discouraged were tightly linked to emotional well-being. Difficulty concentrating was the single strongest correlate of reduced cognitive quality of life.18PubMed Central. Patient reported symptoms associated with quality of life during chemo- or immunotherapy for bladder cancer patients with advanced disease
This matters because fatigue and mood changes are easy to dismiss as “just part of having cancer,” but they are treatable symptoms that deserve attention. If you are on immunotherapy and finding that exhaustion, low mood, or brain fog is eroding your quality of life, raising those with your oncology team can lead to meaningful interventions, whether that is dose timing adjustments, referral to supportive care, or evaluation for an underlying endocrine side effect that is mimicking general cancer fatigue.
Rare Side Effects You Should Know About
Beyond the common organ-specific side effects, checkpoint inhibitors can cause a wide array of uncommon reactions, defined as those occurring in fewer than 1% of patients. These include inflammation of the heart muscle (myocarditis), neurological conditions like encephalitis or Guillain-Barré syndrome, kidney inflammation, and eye problems like uveitis. As checkpoint inhibitors are prescribed more widely and for more cancer types and stages, these rare events are being seen more frequently in absolute numbers.3PubMed Central. Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy
Myocarditis deserves special mention because, while rare, it carries the highest fatality rate among immune-related adverse events. Symptoms can include chest pain, shortness of breath, palpitations, or sudden exercise intolerance. Because of its severity, many oncology centers now include baseline cardiac biomarkers before starting checkpoint inhibitor therapy, so they have a comparison point if cardiac symptoms develop later.
The Gut Microbiome and Side Effect Risk
One of the more intriguing research directions involves the gut microbiome, the community of bacteria living in your intestines. Studies have found correlations between gut bacterial composition and both the response to immunotherapy and the likelihood of developing side effects.19PubMed Central. The Role of the Gut Microbiome in Cancer Immunotherapy: Current Knowledge and Future Directions The research is still early, and no one can yet prescribe a specific probiotic regimen to prevent immune-related colitis or improve treatment response. But it is an active area of investigation, and patients are increasingly asking about it. For now, the honest answer is that your gut bacteria probably matter, but we do not yet know enough to act on that knowledge in a clinically reliable way.
Predicting Who Will Have Severe Reactions
One of the biggest frustrations with checkpoint inhibitor side effects is that they are hard to predict. Two patients with similar bladder cancers, similar health profiles, and the same drug can have completely different experiences. Researchers are actively searching for biomarkers, measurable signals in blood or tissue, that could identify patients at high risk for severe reactions before they happen.20PubMed Central. Predictive Biomarkers of Severe Immune-Related Adverse Events With Immune Checkpoint Inhibitors: Prevention, Underlying Causes, Intensity, and Consequences Some candidates include pre-existing autoantibodies, baseline levels of certain inflammatory markers, and specific genetic variants in immune-related genes. None of these has yet been validated well enough for routine clinical use, but the field is moving fast.
What clinicians can say with some confidence is that patients with pre-existing autoimmune conditions face higher risks, and that combination immunotherapy (using two checkpoint inhibitors together) produces higher rates and greater severity of side effects than single-agent treatment. Beyond that, the prediction remains imprecise, which is part of why ongoing monitoring throughout treatment is so important.
Older Adults and Immunotherapy Tolerance
Bladder cancer is predominantly a disease of older adults, with a median diagnosis age in the mid-70s. This raises natural questions about whether elderly patients handle immunotherapy side effects differently. The available evidence is somewhat reassuring: checkpoint inhibitors appear to be generally well tolerated and effective in older patients.21PubMed Central. Treatment of Urothelial Cancer in Elderly Patients: Focus on Immune Checkpoint Inhibitors Unlike traditional chemotherapy, checkpoint inhibitors do not cause the same degree of bone marrow suppression and nausea that can be especially hard on older patients with less physiological reserve. However, older adults often have more co-existing health conditions and take more medications, which can complicate both the recognition and management of immune-related side effects. An underactive thyroid caused by immunotherapy, for example, is harder to spot in someone who is already on thyroid medication for another reason.
Financial Burden as a Side Effect
Side effects are not just physical. Immunotherapy is expensive, and the financial strain of treatment, sometimes called financial toxicity, is a real and documented problem for patients and their caregivers. Treatment costs, insurance copays, time off work, and the ancillary expenses of managing side effects (additional medications, emergency visits, specialist consultations) can add up quickly. Research has explored how financial toxicity affects advanced cancer patients receiving immunotherapy, with the added pressures of recent inflation and the disruptions caused by the COVID-19 pandemic compounding the problem.22PubMed. Financial toxicity of total cancer care immunotherapy patients and caregivers: impacts of COVID-19 pandemic and inflation If the financial weight of treatment is affecting your decisions or your well-being, most cancer centers have financial counselors and social workers who can help navigate assistance programs and insurance appeals. It is worth asking about early in the treatment process rather than after bills have accumulated.